HONG KONG – In a $120 million deal focused on the greater China region, Glenmark Pharmaceuticals Ltd. joined hands with China's Harbour Biomed Therapeutics Ltd. to co-develop the U.S. company's bispecific antibody (bsAb), GBR-1302, for treating HER2-positive cancers, including breast, gastric and ovarian cancers.